A technetium-labeled monoclonal antibody for imaging metastatic melanoma

Am J Clin Oncol. 1991 Apr;14(2):156-61. doi: 10.1097/00000421-199104000-00012.

Abstract

Twenty patients with histologically proven metastatic melanoma were scanned with a 99mtechnetium (99mTc)-labeled melanoma antibody to determine the detection rate of known malignant lesions and to evaluate the antibody's ability to discover occult metastases. Isotope localization in different organs was as follows: liver 100%, bone 100%, subcutaneous lesions 80%, lymph nodes 54%, and lung 33%. Four unsuspected bone lesions and 16 occult subcutaneous lesions were found. False positive lesions were noted in two instances--one benign thyroid adenoma, and one arthritic bone lesion. One patient developed an atypical serum sickness reaction with a rash and arthralgias that responded rapidly to treatment. The 99mTc antimelanoma antibody is a safe and effective method to detect metastatic melanoma. It has potential use for screening newly diagnosed melanomas that carry an increased risk of recurrence.

MeSH terms

  • Aged
  • Antibodies, Monoclonal*
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / secondary
  • Female
  • Humans
  • Immunoglobulin Fab Fragments*
  • Immunoglobulin G*
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / secondary
  • Male
  • Melanoma / diagnostic imaging
  • Melanoma / secondary*
  • Middle Aged
  • Neoplasms, Unknown Primary / diagnosis
  • Skin Neoplasms / diagnostic imaging
  • Skin Neoplasms / secondary
  • Technetium*
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Immunoglobulin G
  • Technetium